These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

341 related articles for article (PubMed ID: 13677549)

  • 1. Cycle control, tolerability, and satisfaction among women switching from 30-35 microg ethinyl estradiol-containing oral contraceptives to the triphasic norgestimate/25 microg ethinyl estradiol-containing oral contraceptive Ortho Tri-Cyclen LO.
    Poindexter AN; Burkman R; Fisher AC; LaGuardia KD
    Int J Fertil Womens Med; 2003; 48(4):163-72. PubMed ID: 13677549
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of a novel norgestimate/ethinyl estradiol oral contraceptive (Ortho Tri-Cyclen Lo) with the oral contraceptive Loestrin Fe 1/20.
    Hampton RM; Short M; Bieber E; Bouchard C; Ayotte N; Shangold G; Fisher AC; Creasy GW
    Contraception; 2001 Jun; 63(6):289-95. PubMed ID: 11672549
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy, safety and cycle control of five oral contraceptive regimens containing norgestimate and ethinyl estradiol.
    LaGuardia KD; Shangold G; Fisher A; Friedman A; Kafrissen M
    Contraception; 2003 Jun; 67(6):431-7. PubMed ID: 12814811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Scheduled and unscheduled bleeding patterns with two combined hormonal contraceptives: application of new recommendations for standardization.
    Hampton RM; Fisher AC; Pagano S; LaGuardia KD
    Fertil Steril; 2009 Aug; 92(2):434-40. PubMed ID: 18930189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical comparison of triphasic norgestimate/35 micrograms ethinyl estradiol and monophasic norethindrone acetate/20 micrograms ethinyl estradiol. Cycle control, lipid effects, and user satisfaction.
    Sulak P; Lippman J; Siu C; Massaro J; Godwin A
    Contraception; 1999 Mar; 59(3):161-6. PubMed ID: 10382078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1991; 36 Suppl 1():25-31. PubMed ID: 1678378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effectiveness of norgestimate and ethinyl estradiol in treating moderate acne vulgaris.
    Lucky AW; Henderson TA; Olson WH; Robisch DM; Lebwohl M; Swinyer LJ
    J Am Acad Dermatol; 1997 Nov; 37(5 Pt 1):746-54. PubMed ID: 9366821
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effect of atazanavir/ritonavir on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy women.
    Zhang J; Chung E; Yones C; Persson A; Mahnke L; Eley T; Xu X; Bertz R
    Antivir Ther; 2011; 16(2):157-64. PubMed ID: 21447864
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy, cycle control, and side effects of low- and lower-dose oral contraceptives: a randomized trial of 20 micrograms and 35 micrograms estrogen preparations.
    Rosenberg MJ; Meyers A; Roy V
    Contraception; 1999 Dec; 60(6):321-9. PubMed ID: 10715366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risk of nonfatal venous thromboembolism in women using a contraceptive transdermal patch and oral contraceptives containing norgestimate and 35 microg of ethinyl estradiol.
    Jick SS; Kaye JA; Russmann S; Jick H
    Contraception; 2006 Mar; 73(3):223-8. PubMed ID: 16472560
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of efavirenz on the pharmacokinetics of an oral contraceptive containing ethinyl estradiol and norgestimate in healthy HIV-negative women.
    Sevinsky H; Eley T; Persson A; Garner D; Yones C; Nettles R; Krantz K; Bertz R; Zhang J
    Antivir Ther; 2011; 16(2):149-56. PubMed ID: 21447863
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous oral contraceptives: are bleeding patterns dependent on the hormones given?
    Edelman AB; Koontz SL; Nichols MD; Jensen JT
    Obstet Gynecol; 2006 Mar; 107(3):657-65. PubMed ID: 16507938
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of alitretinoin on the pharmacokinetics of the oral contraceptive ethinyl estradiol/norgestimate.
    Schmitt-Hoffmann AH; Roos B; Sauer J; Schleimer M; Schoetzau A; Leese PT; Weidekamm E; Maares J
    Clin Exp Dermatol; 2011 Apr; 36 Suppl 2():4-11. PubMed ID: 21443598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of the coadministration of daclatasvir on the pharmacokinetics of a combined oral contraceptive containing ethinyl estradiol and norgestimate.
    Bifano M; Sevinsky H; Hwang C; Kandoussi H; Jiang H; Grasela D; Bertz R
    Antivir Ther; 2014; 19(5):511-9. PubMed ID: 24343001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cycle control with triphasic norgestimate and ethinyl estradiol, a new oral contraceptive agent.
    Andolsek KM
    Acta Obstet Gynecol Scand Suppl; 1992; 156():22-6. PubMed ID: 1324553
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Superiority of a combined contraceptive containing drospirenone to a triphasic preparation containing norgestimate in acne treatment.
    Thorneycroft lH; Gollnick H; Schellschmidt I
    Cutis; 2004 Aug; 74(2):123-30. PubMed ID: 15379365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Individualization of low-dose oral contraceptives. Pharmacological principles and practical indications for oral contraceptives].
    Cianci A; De Leo V
    Minerva Ginecol; 2007 Aug; 59(4):415-25. PubMed ID: 17923832
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical experience with a new norgestimate-containing oral contraceptive.
    Huber J
    Int J Fertil; 1992; 37 Suppl 1():47-53. PubMed ID: 1347520
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of a new 24-day oral contraceptive regimen of norethindrone acetate 1 mg/ethinyl estradiol 20 micro g (Loestrin 24 Fe).
    Nakajima ST; Archer DF; Ellman H
    Contraception; 2007 Jan; 75(1):16-22. PubMed ID: 17161118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
    Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
    Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.